NASDAQ:ASNS

Arsanis Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$3.11
0.00 (0.00 %)
(As of 03/13/2019)
Add
Compare
Today's Range
$3.05
Now: $3.11
$3.78
50-Day Range
$3.11
MA: $3.11
$3.11
52-Week Range
$1.15
Now: $3.11
$28.69
Volume607,244 shs
Average Volume62,844 shs
Market Capitalization$45.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8

Competitors

Arsanis (NASDAQ:ASNS) Vs. LBPH, GANX, ANVS, EVAX, LGVN, and CMMB

Should you be buying ASNS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Arsanis, including Longboard Pharmaceuticals (LBPH), Gain Therapeutics (GANX), Annovis Bio (ANVS), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), and Chemomab Therapeutics (CMMB).

Longboard Pharmaceuticals (NASDAQ:LBPH) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Longboard Pharmaceuticals and Arsanis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/AN/AN/AN/A
Arsanis$3.50 million13.01$-33,870,000.00($16.23)-0.19

Longboard Pharmaceuticals has higher earnings, but lower revenue than Arsanis.

Insider and Institutional Ownership

77.4% of Arsanis shares are owned by institutional investors. 50.9% of Arsanis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Longboard Pharmaceuticals and Arsanis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Longboard PharmaceuticalsN/AN/AN/A
ArsanisN/A-126.85%-82.61%

Analyst Recommendations

This is a summary of recent ratings for Longboard Pharmaceuticals and Arsanis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longboard Pharmaceuticals00503.00
Arsanis0000N/A

Longboard Pharmaceuticals presently has a consensus target price of $32.75, suggesting a potential upside of 223.30%. Given Longboard Pharmaceuticals' higher probable upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than Arsanis.

Summary

Longboard Pharmaceuticals beats Arsanis on 4 of the 7 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Arsanis and Gain Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arsanis$3.50 million13.01$-33,870,000.00($16.23)-0.19
Gain TherapeuticsN/AN/AN/AN/AN/A

Gain Therapeutics has lower revenue, but higher earnings than Arsanis.

Institutional & Insider Ownership

77.4% of Arsanis shares are owned by institutional investors. 50.9% of Arsanis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Arsanis and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ArsanisN/A-126.85%-82.61%
Gain TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Arsanis and Gain Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arsanis0000N/A
Gain Therapeutics00203.00

Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 114.75%. Given Gain Therapeutics' higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Arsanis.

Summary

Gain Therapeutics beats Arsanis on 4 of the 7 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Profitability

This table compares Arsanis and Annovis Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ArsanisN/A-126.85%-82.61%
Annovis BioN/AN/AN/A

Institutional & Insider Ownership

77.4% of Arsanis shares are owned by institutional investors. 50.9% of Arsanis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Arsanis and Annovis Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arsanis$3.50 million13.01$-33,870,000.00($16.23)-0.19
Annovis BioN/AN/AN/AN/AN/A

Annovis Bio has lower revenue, but higher earnings than Arsanis.

Analyst Ratings

This is a breakdown of current ratings and price targets for Arsanis and Annovis Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arsanis0000N/A
Annovis Bio0000N/A

Summary

Arsanis beats Annovis Bio on 3 of the 5 factors compared between the two stocks.

Evaxion Biotech A/S (NASDAQ:EVAX) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Evaxion Biotech A/S and Arsanis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Arsanis0000N/A

Evaxion Biotech A/S currently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher possible upside, equities research analysts plainly believe Evaxion Biotech A/S is more favorable than Arsanis.

Profitability

This table compares Evaxion Biotech A/S and Arsanis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
ArsanisN/A-126.85%-82.61%

Valuation & Earnings

This table compares Evaxion Biotech A/S and Arsanis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
Arsanis$3.50 million13.01$-33,870,000.00($16.23)-0.19

Evaxion Biotech A/S has higher earnings, but lower revenue than Arsanis.

Institutional & Insider Ownership

77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Evaxion Biotech A/S beats Arsanis on 4 of the 7 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Institutional and Insider Ownership

77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Arsanis and Longeveron, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arsanis0000N/A
Longeveron0000N/A

Profitability

This table compares Arsanis and Longeveron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ArsanisN/A-126.85%-82.61%
LongeveronN/AN/AN/A

Earnings and Valuation

This table compares Arsanis and Longeveron's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arsanis$3.50 million13.01$-33,870,000.00($16.23)-0.19
LongeveronN/AN/AN/AN/AN/A

Longeveron has lower revenue, but higher earnings than Arsanis.

Summary

Arsanis beats Longeveron on 3 of the 5 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arsanis and Chemomab Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arsanis0000N/A
Chemomab Therapeutics0000N/A

Earnings & Valuation

This table compares Arsanis and Chemomab Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arsanis$3.50 million13.01$-33,870,000.00($16.23)-0.19
Chemomab TherapeuticsN/AN/AN/AN/AN/A

Chemomab Therapeutics has lower revenue, but higher earnings than Arsanis.

Institutional & Insider Ownership

77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Arsanis and Chemomab Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ArsanisN/A-126.85%-82.61%
Chemomab TherapeuticsN/AN/AN/A

Summary

Arsanis beats Chemomab Therapeutics on 3 of the 5 factors compared between the two stocks.


Arsanis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LBPH
Longboard Pharmaceuticals
1.9$10.13flat$171.37 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.97flat$158.29 millionN/A0.00Analyst Report
News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.95flat$152.49 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$6.85flat$131.51 millionN/A0.00
LGVN
Longeveron
0.3$6.23flat$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$34.49flat$80.60 millionN/A0.00High Trading Volume
News Coverage
Gap Up
Trading Halted
UPC
Universe Pharmaceuticals
0.0$3.55flat$77.21 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.04flat$58.78 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.19flat$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.59flat$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.55flat$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.46flat$38.08 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$2.91flat$34.28 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.39flat$29.90 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.26flat$21.07 millionN/A0.00News Coverage
Gap Up
BCTX
BriaCell Therapeutics
0.0$3.12flat$2.41 millionN/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.56flat$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08flat$0.00N/A0.00Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06flat$0.00N/A0.00
BMEA
Biomea Fusion
0.0$17.00flat$0.00N/A0.00High Trading Volume
Gap Up
RXRX
Recursion Pharmaceuticals
0.0$28.00flat$0.00N/A0.00High Trading Volume
Gap Up
RPHM
Reneo Pharmaceuticals
0.3$12.72flat$0.00N/A0.00
SCPS
Scopus BioPharma
1.4$7.70flat$0.00N/A0.00Increase in Short Interest
VECT
VectivBio
0.0$15.25flat$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.